A multiplex protein panel assay determines disease severity and is prognostic about outcome in COVID-19 patients
A multiplex protein panel assay determines disease severity and is prognostic about outcome in COVID-19 patients
Abstract Global healthcare systems continue to be challenged by the COVID-19 pandemic, and there is a need for clinical assays that can both help to optimize resource allocation and accelerate the development and evaluation of new therapies. Here, we present a multiplex proteomic panel assay for the assessment of disease severity and outcome prediction in COVID-19. The assay quantifies 50 peptides derived from 30 COVID-19 severity markers in a single measurement using analytical flow rate liquid chromatography and multiple reaction monitoring (LC-MRM), on equipment that is broadly available in routine and regulated analytical laboratories. We demonstrate accurate classification of COVID-19 severity in patients from two cohorts. Furthermore, the assay outperforms established risk assessments such as SOFA and APACHE II in predicting survival in a longitudinal COVID-19 cohort. The prognostic value implies its use for support of clinical decisions in settings with overstrained healthcare resources e.g. to optimally allocate resources to severely ill individuals with high chance of survival. It can furthermore be helpful for monitoring of novel therapies in clinical trials.
M¨1lleder Michael、Zeiser Johannes、Townsend StJohn、Demichev Vadim、Sirka Ernestas、Hartl Johannes、Lemke Oliver、Ludwig Daniela、Helbig Elisa Theresa、Mueller Christoph、Wang Ziyue、Lane Catherine S、Kurth Florian、Blake Daniel、Ralser Markus、Sayers Rebekah L、Tober-Lau Pinkus、Cryar Adam
Core Facility ¨C High-Throughput Mass Spectrometry, Charit¨| ¨C Universit?tsmedizin Berlin, Corporate Member of Freie Universit?t Berlin and Humboldt-Universit?t zu Berlin, Core Facility ¨C High-Throughput Mass SpectrometryAgilent Technologies Sales & Services GmbH & Co. KGDepartment of Biochemistry, Charit¨| ¨C Universit?tsmedizin Berlin, Corporate Member of Freie Universit?t Berlin and Humboldt-Universit?t zu BerlinDepartment of Biochemistry, Charit¨| ¨C Universit?tsmedizin Berlin, Corporate Member of Freie Universit?t Berlin and Humboldt-Universit?t zu BerlinInovivDepartment of Biochemistry, Charit¨| ¨C Universit?tsmedizin Berlin, Corporate Member of Freie Universit?t Berlin and Humboldt-Universit?t zu BerlinDepartment of Biochemistry, Charit¨| ¨C Universit?tsmedizin Berlin, Corporate Member of Freie Universit?t Berlin and Humboldt-Universit?t zu BerlinDepartment of Biochemistry, Charit¨| ¨C Universit?tsmedizin Berlin, Corporate Member of Freie Universit?t Berlin and Humboldt-Universit?t zu BerlinDepartment of Infectious Diseases and Respiratory Medicine, Charit¨| ¨C Universit?tsmedizin Berlin, corporate member of Freie Universit?t Berlin and Humboldt-Universit?t zu BerlinAgilent Technologies Sales & Services GmbH & Co. KGDepartment of Biochemistry, Charit¨| ¨C Universit?tsmedizin Berlin, Corporate Member of Freie Universit?t Berlin and Humboldt-Universit?t zu BerlinSCIEX, MacclesfieldDepartment of Infectious Diseases and Respiratory Medicine, Charit¨| ¨C Universit?tsmedizin Berlin, corporate member of Freie Universit?t Berlin and Humboldt-Universit?t zu Berlin||Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Medicine I, University Medical Centre Hamburg-EppendorfSCIEX, MacclesfieldDepartment of Biochemistry, Charit¨| ¨C Universit?tsmedizin Berlin, Corporate Member of Freie Universit?t Berlin and Humboldt-Universit?t zu BerlinSCIEX, MacclesfieldDepartment of Infectious Diseases and Respiratory Medicine, Charit¨| ¨C Universit?tsmedizin Berlin, corporate member of Freie Universit?t Berlin and Humboldt-Universit?t zu BerlinInoviv
医学研究方法临床医学基础医学
M¨1lleder Michael,Zeiser Johannes,Townsend StJohn,Demichev Vadim,Sirka Ernestas,Hartl Johannes,Lemke Oliver,Ludwig Daniela,Helbig Elisa Theresa,Mueller Christoph,Wang Ziyue,Lane Catherine S,Kurth Florian,Blake Daniel,Ralser Markus,Sayers Rebekah L,Tober-Lau Pinkus,Cryar Adam.A multiplex protein panel assay determines disease severity and is prognostic about outcome in COVID-19 patients[EB/OL].(2025-03-28)[2025-06-12].https://www.medrxiv.org/content/10.1101/2021.12.03.21267253.点此复制
评论